Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib

Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib

Abstract This is the first case report of a non‐small‐cell lung cancer (NSCLC) patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del treated with first‐line alectinib. Approximately 5% of NSCLC patients are reported to have anaplastic lymphoma kinase (ALK) rearrangements, and among these EML4‐ALK...

Full description

Saved in:
Bibliographic Details
Main Authors: Vito Longo, Francesco Pesola, Rosanna Lacalamita, Annamaria Catino, Michele Montrone, Ilaria Marech, Pamela Pizzutilo, Elisabetta Sara Montagna, Stefania Tommasi, Domenico Galetta
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Thoracic Cancer
Subjects:
HIP1‐ALK (H28:A20)
CTNNB1 p.S45del
Alectinib
Online Access:https://doi.org/10.1111/1759-7714.15397
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.15397

Similar Items